Developer docs
API playgroundTry for free, no card

Search company profiles

Ideal Medical Technologies

Full company profile

uuid00052jq

Namestring
Ideal Medical Technologies
Legal namestring
Ideal Medical Technologies, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Ideal Medical Technologies (IMT) is an Asheville, North Carolina-based medical device company developing the FUSION system, an AI-based closed-loop glucose control platform (described as an artificial pancreas) intended for use in hospital intensive care units. The system integrates continuous glucose monitoring hardware (Dexcom G6 or EIRUS CGM), a Teguar medical computer running proprietary AI control software, and Enovate-powered medical cart housing syringe pumps to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. The proprietary algorithms mimic native pancreas and liver glucose control mechanisms derived from a peer-reviewed 2010 publication, and in a first-in-human study (May 2023, 7 participants) the system achieved 87.8% time in range 70-180 mg/dL with only 0.2% time below range and a coefficient of variation of 19.4%.

The company's regulatory pathway is well-defined: the FDA designated FUSION as a Breakthrough Medical Device in March 2019, multiple IDE approvals have been secured (March 2021, February 2025 software update, December 2025 new IDE), and a 2023 pre-submission meeting confirmed commercial clearance will be sought via the 510(k) pathway. The company has received $1.9M in non-dilutive funding through an NIH SBIR Phase II grant (June 2022), supplemented by a $200,000 raise in May 2020; no venture or private equity capital has been disclosed. Founder Dr. Leon DeJournett (CEO) leads with over 30 years of ICU experience, supported by CTO Jeremy DeJournett and clinical collaboration with Dr. Francisco Pasquel of Emory University, who led the first-in-human study.

IMT's planned go-to-market targets hospital ICU departments with a B2B enterprise sales model selling the complete FUSION system (hardware plus software) likely via hospital procurement and Group Purchasing Organization (GPO) contracts. Pricing is not publicly disclosed and the company remains pre-revenue pending 510(k) clearance. Future product iterations are described as potentially expanding to control additional ICU parameters including osmolality, intravascular volume status, and blood pressure.

Short descriptiontext

Ideal Medical Technologies develops the FUSION system, an AI-based closed-loop glucose control platform for hospital ICU patients that autonomously adjusts intravenous insulin and dextrose infusions using continuous glucose monitoring data, targeting B2B sales to hospital intensive care units.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAsheville, United States
HQ citystring
Asheville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
closed-loop glucose control, artificial pancreas systems, ICU medical devices, AI glucose management, automated insulin delivery
Industry2 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices (ICU Glucose Control)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1FUSION System Hardware and Software
TypeHardware Sales
Description

Medical device combining proprietary AI software with hardware components (Dexcom G6 CGM, medical computer, syringe pumps, powered medical cart). Revenue will come from sale of the complete FUSION system to hospital ICUs.

idealmedtech.com
2AI Glucose Control Software Licensing
TypeLicensing Royalties
Description

Proprietary AI-based glucose control software forms the core technology, potentially licensed separately or bundled with hardware. The software received Breakthrough Medical Device designation from FDA in March 2019.

idealmedtech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1No pricing tiers publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Medical device pricing typically determined through hospital procurement and GPO contracts.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FUSION
Description

An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients that automatically adjusts intravenous insulin and dextrose infusions.

Core offering1 text field

Ideal Medical Technologies develops and plans to commercialize the FUSION System, an AI-driven, closed-loop glucose control system (artificial pancreas) designed for hospital ICU patients. The system integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with proprietary AI control software running on approved medical computing hardware, autonomously adjusting intravenous insulin and dextrose infusion rates every 5-10 minutes to maintain tight glucose control. Revenue is expected from sale of the complete FUSION system to hospital ICUs, with potential licensing of the core AI software.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Reduces nursing time from 1-2 hours to 20 minutes per patient per day
+7 more records
Product overview1 text field

Ideal Medical Technologies offers a single unified product: the FUSION System, an artificially intelligent closed-loop glucose control system (artificial pancreas) designed for ICU patients. The FUSION System is a modular platform that integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with AI-based control software running on approved medical computing hardware, connected to syringe pumps for automated insulin and dextrose delivery. The system operates autonomously, requiring only 20 minutes of daily nursing time versus the current standard of care that requires 1-2 hours per patient per day.

Product and service1 record
1FUSION System
CategoryICU Glucose Control Medical Device
Description

An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients. The system continuously reads glucose values from a continuous glucose monitor (e.g., Dexcom G6) and uses proprietary AI-based expert rule software to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. Indicated for ICU patients requiring tight glucose control, including those with diabetes and stress-induced hyperglycemia.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative agreement with Emory University for clinical studies of FUSION system. Clinical studies led by Dr. Francisco Pasquel, one of the world's foremost authorities on inpatient glucose control. First-in-human study performed at Emory under FDA IDE approval.

Strategic tierCoreTypeTechnology or Integration
Description

Software experts at Velentium (chosen OEM) worked with IMT to ensure FUSION system software documentation adheres to new FDA standards released in June 2023. Velentium is responsible for transferring FUSION device specifications to contract manufacturer for commercial grade version.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as collaborator on company website, indicating regional partnership for biotech development support in North Carolina.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

Insulet's Omnipod 5 is an automated insulin delivery system for outpatient diabetes management. It shares the AID/closed-loop category with FUSION but targets a different care setting.

TypeBroad incumbent
Description

Medtronic offers the MiniMed 780G, an outpatient artificial pancreas system, and is a dominant player in insulin pumps and CGM-integration. While not focused on the ICU, its diabetes franchise and resources could expand into inpatient automated glucose control.

TypeEmerging player
Description

Tandem Diabetes Care markets the t:slim X2 with Control-IQ, an automated insulin delivery system for outpatient use. It is comparable to FUSION as a closed-loop insulin delivery technology, though serving the outpatient diabetes market rather than the ICU.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the global CGM market leader. While primarily a CGM and broader diagnostics incumbent, its hospital-grade CGM offerings overlap with the continuous glucose monitoring layer that FUSION depends on.

TypeEmerging player
Description

Beta Bionics developed the iLet bionic pancreas, an automated insulin delivery system. While focused on outpatient diabetes rather than ICU use, it shares the artificial pancreas / closed-loop insulin delivery technology category with FUSION.

TypeDirect peer
Description

Glytec offers the eGlycemic Management System, a software-as-a-medical-device platform for insulin dosing in hospitals. It directly competes with FUSION in the hospital glucose management category, although Glytec's offering is currently software-guided rather than fully closed-loop/autonomous.

TypeOthers
Description

Dexcom manufactures the G6 CGM that FUSION integrates with as a glucose input. It is an enabling technology partner/supplier rather than a direct competitor, but a key ecosystem dependency for FUSION's product architecture.

TypeDirect peer
Description

Admetsys develops an automated insulin dosing system for hospital and surgical ICU patients. It is the most direct competitor to Ideal Medical Technologies, also targeting fully autonomous glucose control in the inpatient ICU setting with similar regulatory positioning.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ideal Medical Technologies

Medical Devices (ICU Glucose Control)idealmedtech.com

Ideal Medical Technologies develops the FUSION system, an AI-based closed-loop glucose control platform for hospital ICU patients that autonomously adjusts intravenous insulin and dextrose infusions using continuous glucose monitoring data, targeting B2B sales to hospital intensive care units.

What Ideal Medical Technologies does

Ideal Medical Technologies (IMT) is an Asheville, North Carolina-based medical device company developing the FUSION system, an AI-based closed-loop glucose control platform (described as an artificial pancreas) intended for use in hospital intensive care units. The system integrates continuous glucose monitoring hardware (Dexcom G6 or EIRUS CGM), a Teguar medical computer running proprietary AI control software, and Enovate-powered medical cart housing syringe pumps to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. The proprietary algorithms mimic native pancreas and liver glucose control mechanisms derived from a peer-reviewed 2010 publication, and in a first-in-human study (May 2023, 7 participants) the system achieved 87.8% time in range 70-180 mg/dL with only 0.2% time below range and a coefficient of variation of 19.4%.

The company's regulatory pathway is well-defined: the FDA designated FUSION as a Breakthrough Medical Device in March 2019, multiple IDE approvals have been secured (March 2021, February 2025 software update, December 2025 new IDE), and a 2023 pre-submission meeting confirmed commercial clearance will be sought via the 510(k) pathway. The company has received $1.9M in non-dilutive funding through an NIH SBIR Phase II grant (June 2022), supplemented by a $200,000 raise in May 2020; no venture or private equity capital has been disclosed. Founder Dr. Leon DeJournett (CEO) leads with over 30 years of ICU experience, supported by CTO Jeremy DeJournett and clinical collaboration with Dr. Francisco Pasquel of Emory University, who led the first-in-human study.

IMT's planned go-to-market targets hospital ICU departments with a B2B enterprise sales model selling the complete FUSION system (hardware plus software) likely via hospital procurement and Group Purchasing Organization (GPO) contracts. Pricing is not publicly disclosed and the company remains pre-revenue pending 510(k) clearance. Future product iterations are described as potentially expanding to control additional ICU parameters including osmolality, intravascular volume status, and blood pressure.

Ideal Medical Technologies firmographics

Firmographics
Name
Ideal Medical Technologies
Legal name
Ideal Medical Technologies, Inc.
Website
https://idealmedtech.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Ideal Medical Technologies develops the FUSION system, an AI-based closed-loop glucose control platform for hospital ICU patients that autonomously adjusts intravenous insulin and dextrose infusions using continuous glucose monitoring data, targeting B2B sales to hospital intensive care units.
Ownership category
akta.pro rank

Ideal Medical Technologies industry classification

Industry
Product category
Medical Devices (ICU Glucose Control)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Closed-loop glucose control
  • Artificial pancreas systems
  • ICU medical devices
  • AI glucose management
  • Automated insulin delivery

Where Ideal Medical Technologies is headquartered

Location

Headquarters

HQ city
Asheville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ideal Medical Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. FUSION System Hardware and Software: Medical device combining proprietary AI software with hardware components (Dexcom G6 CGM, medical computer, syringe pumps, powered medical cart). Revenue will come from sale of the complete FUSION system to hospital ICUs.
  2. AI Glucose Control Software Licensing: Proprietary AI-based glucose control software forms the core technology, potentially licensed separately or bundled with hardware. The software received Breakthrough Medical Device designation from FDA in March 2019.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo pricing tiers publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Ideal Medical Technologies product offering

Product offering

Core offering

Ideal Medical Technologies develops and plans to commercialize the FUSION System, an AI-driven, closed-loop glucose control system (artificial pancreas) designed for hospital ICU patients. The system integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with proprietary AI control software running on approved medical computing hardware, autonomously adjusting intravenous insulin and dextrose infusion rates every 5-10 minutes to maintain tight glucose control. Revenue is expected from sale of the complete FUSION system to hospital ICUs, with potential licensing of the core AI software.

Product overview

Ideal Medical Technologies offers a single unified product: the FUSION System, an artificially intelligent closed-loop glucose control system (artificial pancreas) designed for ICU patients. The FUSION System is a modular platform that integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with AI-based control software running on approved medical computing hardware, connected to syringe pumps for automated insulin and dextrose delivery. The system operates autonomously, requiring only 20 minutes of daily nursing time versus the current standard of care that requires 1-2 hours per patient per day.

Differentiator

Problem solved

Functional benefit

Brands

  • FUSION: An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients that automatically adjusts intravenous insulin and dextrose infusions.

Products and services

  • FUSION System An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients. The system continuously reads glucose values from a continuous glucose monitor (e.g., Dexcom G6) and uses proprietary AI-based expert rule software to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. Indicated for ICU patients requiring tight glucose control, including those with diabetes and stress-induced hyperglycemia.

Quantifiable outcome

  • Reduces nursing time from 1-2 hours to 20 minutes per patient per day
  • +7 more outcomes

Companies that use Ideal Medical Technologies

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Ideal Medical Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature4 records

Ideal Medical Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Emory UniversitycoreStrategic or Co-development PartnerCollaborative agreement with Emory University for clinical studies of FUSION system. Clinical studies led by Dr. Francisco Pasquel, one of the world's foremost authorities on inpatient glucose control. First-in-human study performed at Emory under FDA IDE approval.
  • VelentiumcoreTechnology or IntegrationSoftware experts at Velentium (chosen OEM) worked with IMT to ensure FUSION system software documentation adheres to new FDA standards released in June 2023. Velentium is responsible for transferring FUSION device specifications to contract manufacturer for commercial grade version.
  • North Carolina Biotechnology CenterminorStrategic or Co-development PartnerListed as collaborator on company website, indicating regional partnership for biotech development support in North Carolina.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Ideal Medical Technologies competitors and assessment

Company assessment

Emerging players

  • Insulet: Insulet's Omnipod 5 is an automated insulin delivery system for outpatient diabetes management. It shares the AID/closed-loop category with FUSION but targets a different care setting.
  • Tandem Diabetes Care: Tandem Diabetes Care markets the t:slim X2 with Control-IQ, an automated insulin delivery system for outpatient use. It is comparable to FUSION as a closed-loop insulin delivery technology, though serving the outpatient diabetes market rather than the ICU.
  • Beta Bionics: Beta Bionics developed the iLet bionic pancreas, an automated insulin delivery system. While focused on outpatient diabetes rather than ICU use, it shares the artificial pancreas / closed-loop insulin delivery technology category with FUSION.

Broad incumbents

  • Medtronic: Medtronic offers the MiniMed 780G, an outpatient artificial pancreas system, and is a dominant player in insulin pumps and CGM-integration. While not focused on the ICU, its diabetes franchise and resources could expand into inpatient automated glucose control.
  • Abbott Diabetes Care: Abbott's FreeStyle Libre is the global CGM market leader. While primarily a CGM and broader diagnostics incumbent, its hospital-grade CGM offerings overlap with the continuous glucose monitoring layer that FUSION depends on.

Direct peers

  • Glytec: Glytec offers the eGlycemic Management System, a software-as-a-medical-device platform for insulin dosing in hospitals. It directly competes with FUSION in the hospital glucose management category, although Glytec's offering is currently software-guided rather than fully closed-loop/autonomous.
  • Admetsys: Admetsys develops an automated insulin dosing system for hospital and surgical ICU patients. It is the most direct competitor to Ideal Medical Technologies, also targeting fully autonomous glucose control in the inpatient ICU setting with similar regulatory positioning.

Others

  • Dexcom: Dexcom manufactures the G6 CGM that FUSION integrates with as a glucose input. It is an enabling technology partner/supplier rather than a direct competitor, but a key ecosystem dependency for FUSION's product architecture.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ideal Medical Technologies compliance and trust

Trust signal

Compliance4 records

Ideal Medical Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ideal Medical Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Ideal Medical Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ideal Medical Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ideal Medical Technologies

What does Ideal Medical Technologies do?

Ideal Medical Technologies develops and plans to commercialize the FUSION System, an AI-driven, closed-loop glucose control system (artificial pancreas) designed for hospital ICU patients. The system integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with proprietary AI control software running on approved medical computing hardware, autonomously adjusting intravenous insulin and dextrose infusion rates every 5-10 minutes to maintain tight glucose control. Revenue is expected from sale of the complete FUSION system to hospital ICUs, with potential licensing of the core AI software.

Is Ideal Medical Technologies a public or private company?

Ideal Medical Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ideal Medical Technologies founded?

Ideal Medical Technologies was founded in 2014. It employs 1 to 10 people.

Where is Ideal Medical Technologies based?

Ideal Medical Technologies is headquartered in Asheville, United States, in the North America region.

How does Ideal Medical Technologies make money?

Two revenue lines are on record. FUSION System Hardware and Software is the primary driver. The others are AI Glucose Control Software Licensing.

Who are Ideal Medical Technologies's main competitors?

Emerging players on record are Insulet, Tandem Diabetes Care and Beta Bionics. Broad incumbents are Medtronic and Abbott Diabetes Care. Direct peers are Glytec and Admetsys. Dexcom is listed as an others.

Does Ideal Medical Technologies have an API?

No public API is recorded for Ideal Medical Technologies.

What industry is Ideal Medical Technologies in?

Ideal Medical Technologies's product category is Medical Devices (ICU Glucose Control). Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales